Clinical trial
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With…
NCT00428389 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00428389 |
|---|---|
| Title | Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease |
| Official title | A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study With a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching From Donepezil to an Initial Dose of 5 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch |
| Enrollment | 262 |
| Start date | Jan 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jan 30, 2007 |
| Last update posted | Jun 11, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: